|Awarded On||November 20, 2019|
|Title||Recruitment of First-Time, Tenure-Track Faculty Members|
|Award Mechanism||Recruitment of First-Time, Tenure-Track Faculty Members|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Benjamin Drapkin|
|Cancer Sites||Lung and Bronchus|
|Summary of Goals and Objectives||
Small cell lung cancer (SCLC) afflicts more than 30,000 patients per year and is rapidly fatal in 95% of cases, with median survival of less than one year. Although untreated SCLC is highly responsive to first-line chemotherapy, benefit is temporary and following relapse, resistance often extends to a broad spectrum of DNA damaging agents. Also, investigational therapies in clinical trials are often confounded by the same cross-resistance that hinders standard second-line agents.
Although important, cross-resistance is difficult to study experimentally, as it requires a model system that faithfully reproduces clinical out...